The article presents the results of a comprehensive analysis of the effect of simvastatin (at a dose of 20 mg per day) on the functional state of the brain of patients with atherothrombotic ischemic stroke. In patients with ischemic stroke, simvastatin causes vasoactive effect (increases systolic blood flow velocity and decreases peripheral resistance in some vessels of carotid and vertebrobasilar systems), antiatherogenic action (reduces the size of the intima, reduces the frequency of atherosclerotic plaques, lowers cholesterol, triglycerides, LDL). In patients with atherothrombotic ischemic stroke, simvastatin causes a positive reorganization of the bioelectric activity of the brain (increases the frequency of alpha rhythm and reduces the power in the range of slow rhythms), which is more pronounced in patients with localization of the ischemic lesion in the left hemisphere. Complex positive influence of simvastatin on a cerebral hemodynamics, bioelectric activity of brain, lipid metabolism for patients with atherothrombotic ischemic stroke, grounds to recommend application of simvastatin not only for the secondary prevention of stroke but also for the correction of the functional state of CNS for patients with a stroke in the period of rehabilitation.
healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association / American Stroke Association //
Stroke. — 2003. — Vol. 34. — P. 2310-2322.
2. Amarenco P., Bogousslavsky J., Amarenco P. et al. Highdose atorvastatin after stroke or transient ischemic attack // N. Engl. J. Med. — 2006. — 355. —
3. Geyer J.D., Gomez C.R. Stroke. A practical approach. — Lipppicott: Williams&Wilkins, 2009. — P. 36.
4. Giral P., Neumann A., Weill A., Coste J. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France // European Heart Journal. — 2019. — Vol. 40, Issue 43. — P. 3516-3525.
5. Harada M., Miyoshi H., Taoka Y. et al. Accuracy and clinical utility of quantitative proton magnetic resonance spectroscopy (MRS) on phantom and
chronic cerebral ischemia // Nippon Igaku Hoshausen Gakkai Zasshi. — 1996. — 56 (6). — P. 405-410.
6. Hippisley-Cox J., Coupland C. Effect of statins on the mortality of patients with ischemic heart disease: population based cohort study with nested case-control
analysis // Heart. — 2006. — 92 (6). — P. 752-8.
7. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS) // Circulation. — 1998. — 97. —
8. Jayasundar R. human brain: biochemical lateralization in normal subjects // Neurol. India. — 2002. — Vol. 5, № 3.
9. Kumbhani D.J. Treat Stroke to Target — treat Stroke to Target // American College of Cardiology January. — 2020. — Р. 45-50.
10. Kuznetsov V.V., Yurchenko F.V., Schulzenko D.V. Mechanisms of symvastatin’s effect on functional status of CNS in patients with ischemic stroke // Abstract
book (3rd International Conference on Hypertension, Lipids, Diabetes and Stroke Prevention). — Berlin, 2010. — P. 232.
11. Leeanne M. Carey Stroke Rehabilitation. — Oxford University press, 2012.
12. Lorenz M.V., Marcus H.S., Bots M.L., Sitzer M. Prediction of Clinical Cardiovascular Events With Carotid Intima-Media Thickness: A Systematic Rewiew and Meta-Analysis // Circulation. — 2007. — Vol. 115. — P. 459-467.
13. Matthew M.Y. Lee, Naveed Sattar, John J.V. McMurray, and Packard Chris J. Statins in the prevention and treatment of heart failure a review of the evidence. —
14. Mohr J.P., Choi D.W., Gratta J.C. et al. Stroke: pathophysiology / diagnosis, and management. — Philadelphia: Churchill Livingstone, 2004. — 1616 p.
15. O’Donnell M., Xavier D., Liu L. et al. Risk factors for ischemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control
study // Lancet. — 2010. — Vol. 376. — P. 112-123.